Stock Analiz

Biofrontera Inc. BFRI

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$0.70Market cap $10M
Open the interactive analysis →

Biofrontera Inc. (BFRI) is a healthcare company listed in the US with a market value of about $10M. In the twelve months to September 30, 2026 it had revenue of $48M and net income of -$6M, a net margin of -12.7%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is financial health (0/5).

Key numbers: 5-year revenue growth of 17% a year, a 5-year average ROIC of -117%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 222% above the current price.

About Biofrontera

Biofrontera is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $19M in 2020 to $42M in 2025, growth of about 17.2% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 862% over three years (dilution for shareholders). It spends 9% of revenue on research and development.

Score: 1.4 / 5

Value1/5
Future growth4/5
Track record1/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)—
Forward P/E1.4
P/FCF—
P/S0.2
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-53.4%
Shareholder yield0.0%
Intrinsic value vs. price+222%

Growth and quality

Revenue growth (1 yr)11.8%
Revenue growth (5 yrs, per year)17.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-58.1%
ROIC (5-yr avg.)-116.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$48M$42M$37M$34M$29M$24M$19M
Net income-$6M-$11M-$18M-$20M-$640000-$38M-$11M
Free cash flow-$6M-$13M-$10M-$25M-$16M-$27M—
EPS (diluted)$-0.43$-1.04$-3.22$-13.02$-0.61$-85.60$-9589.60
Net margin-12.7%-25.3%-47.6%-59.1%-2.2%-156.5%-58.3%
ROIC—-53.9%-145.3%-175.8%-58.2%-151.5%-130.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $3.00, 329% above the current price; targets range from $3.00 to $3.00; the consensus rating is “Strong buy”; expected EPS is $-0.18 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Biofrontera stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 222% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Biofrontera pay a dividend?

Not currently.

Is Biofrontera a good stock to buy?

We do not give buy or sell advice. Biofrontera scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.